Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NeoTX Therapeutics Ltd.
Travera Inc
NGM Biopharmaceuticals, Inc
Pfizer
NGM Biopharmaceuticals, Inc
Quadriga Biosciences, Inc.
Xencor, Inc.
MacroGenics
Valerio Therapeutics
INSYS Therapeutics Inc
GlaxoSmithKline